BOSTON, Aug 6, 2024 – Remedium Bio announced today the publication of a manuscript titled “Comparative evaluation of rhFGF18 and rhGDF11 treatment in a transient ischemia stroke model” in the peer-reviewed journal Restorative Neurology and Neuroscience. The manuscript highlighted Remedium’s preclinical development of a neuroprotective and neuro-regenerative treatment for cerebral ischemia – RMD1501. Ischemic stroke remains highly underserved, managed by short therapeutic window thrombolytics and mechanical thrombectomies. RMD1501 offers a potential therapeutic alternative with the promise of neuroprotection and neuro-regeneration, having for the first time demonstrated not only reduced infarct volumes and improved motor-cognitive recovery, but also increased survival in models of cerebral ischemia.

“We are extremely excited and honored by the acceptance of our manuscript for publication in Restorative Neurology and Neuroscience” said Frank Luppino, President and CEO of Remedium. “RMD1501 offers a unique therapeutic mechanism in the treatment of cerebral ischemia, with the potential to not only preserve motor-cognitive function, but also increase patient survival should the results translate to clinical efficacy”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jun 13, 2024 – Remedium Bio announces the acceptance of an abstract for the 84th Scientific Sessions of the American Diabetes Association (ADA) annual meeting. This year’s ADA Scientific Sessions are taking place Jun 21st to 24th in Orlando, Florida at the Orange County Convention Center. The American Diabetes Association, formerly founded in 1939, is currently the largest Diabetes-focused non-profit in the United States with a network of 10,000 members and over 500,000 volunteers including healthcare professionals, clinicians, researchers, and industry staff.

Remedium will present the latest update on its first-in-class, disease-modifying gene therapy for the treatment of type 2 diabetes and obesity, RMD1202, delivered with its proprietary Prometheus™ technology. The treatment is intended to enable continuous production of a GLP-1 receptor agonist subcutaneously, the same locale where the therapy would otherwise be injected by a series of daily or weekly protein injections. Remedium’s latest findings suggest that RMD1202 is superior to daily GLP-1 RA protein injections at promoting weight loss, and enables enhanced insulin sensitivity and glucose response over the vehicle control.

“We are very excited by the opportunity to present our work on the first-in-class disease modifying gene therapy treatment for Type 2 Diabetes and Obesity at the American Diabetes Association annual meeting”, said Frank Luppino, President and CEO of Remedium. “The progress made by the team on the development of RMD1202 gives hope of a future where durable, single injection treatment options are available to patients with potentially improved tolerability, due to the zero-order therapeutic kinetics.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, May 14, 2024 – Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™. The manuscript, entitled “Development and characterization of a first-in-class adjustable-dose gene therapy system” was published in the journal Gene.

Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. The system specifically targets adipocytes, with the delivered transgene remaining localized to the site of injection, while the secreted protein biodistributes to the general circulation. The expressed protein kinetics were demonstrated to be zero-order, minimizing potential side effects caused by concentration spikes and suboptimal efficacy at concentration troughs present in a number of current subcutaneously delivered protein therapies.

The publication highlights several key elements of the Prometheus™ technology:

- The vector enables efficient selective transfection of subcutaneous adipocytes, a locally non-life/function sustaining cell with a rich secretome;
- Genetic cargo remains highly localized to the subcutaneous injection site, while the secreted therapeutic protein is biodistributed to the circulation;
- Gene expression is durable and adjustable up or down following initial administration, for the first time enabling full adjustability of a gene therapy treatment;
- The optimized system appears to be well tolerated, while enabling sufficient gene expression to achieve therapeutically relevant levels of secreted proteins in circulation;
- The system can deliver a broad range of genetic cassette sizes, enabling the delivery of cargo encoding peptides to full length antibodies.

Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity. Data from preclinical evaluation of RMD1202 was recently presented at the ASGCT, demonstrating superior efficacy to daily GLP-1 protein injections in a preclinical model of disease. The unique properties of the platform enable delivery of GLP-1, for the first time as a one-time adjustable dose gene therapy, with optimized pharmacokinetics offering the potential for improved tolerability on the backdrop of durable efficacy.

“Our research shows that the Prometheus™ platform overcomes the limitations of today’s gene therapies to enable patients with prevalent chronic diseases to benefit from this revolutionary technology”, said Frank Luppino, President and CEO of Remedium. “We are honored by the opportunity to publish our findings in the peer reviewed journal Gene and view this milestone as a testament to the groundbreaking progress made by the Remedium team”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 11, 2024 – Remedium Bio announced today the acceptance of an abstract titled “Fibroblast Growth Factor 18 Gene Therapy Treatment is Protective to Cartilage and Subchondral Bone in Rat Model of Osteoarthritis” for podium presentation at the 2024 OARSI World Congress. OARSI World Congress is the largest Osteoarthritis-focused conference in the world, bringing together an estimated 1,000 attendees from over 40 countries including investors, orthopedic surgeons, researchers, and policy makers.

“We are honored by OARSI acceptance of our abstract for a prestigious podium presentation at the flagship World Congress event” said Frank Luppino, President and CEO of Remedium. “FGF18 provides the only currently viable mechanism for cartilage regeneration and disease modification in osteoarthritis, and our AAV-mediated approach has shown unique advantages over the alternative of repeat protein injection treatments”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 28, 2024 – Remedium Bio announces the acceptance of an abstract for podium presentation at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The abstract, titled “Development of a First-in-Class Adjustable Dose Gene Therapy Platform and its Application to the Treatment of Type 2 Diabetes and Obesity”, will be presented on May 9th at the Exosomes, Virus Like Particles, and LNPs session. This year’s ASGCT takes place in Baltimore Maryland May 7th through the 11th at the Baltimore Convention Center. The ASGCT is the largest non-profit medical and scientific association of individuals involved in gene and cell therapy research, with close to 5000 members and a nearly 30 year history. Presented abstracts are published in the Society’s journal Molecular Therapy.

Remedium will present an update on the development of RMD1202, a disease modifying treatment for type 2 diabetes and obesity delivered using the first adjustable-dose gene therapy platform technology - Prometheus™. The therapeutic approach is intended to deliver continuous production of GLP-1 subcutaneously, to mediate multi-year efficacy after a single treatment. Preliminary findings suggest that RMD1202 may be able to deliver improved safety and efficacy over repeat protein injections, with better tolerability due to a zero-order delivery kinetics profile.

“We are honored by the selection of our abstract for podium presentation at the 27th ASGCT” said Frank Luppino, President and CEO of Remedium. “Our Prometheus™ platform has the potential to not only improve upon the current GLP-1 approaches, but also a broad range of other recombinant protein treatments, by eliminating the requirement for repeat injections and improving performance via zero-order release kinetics”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 12, 2024 - Remedium Bio announces the acceptance of an abstract titled “A Novel Incretin Gene Therapy Attenuates Hyperglycemia in a Preclinical Model of Type 2 Diabetes” for the 2024 Endocrine Society Annual Meeting (ENDO). This year’s ENDO is taking place June 1st through the 4th in Boston, Massachusetts. The Endocrine Society is an international association of physicians, clinical practitioners, healthcare workers, and scientists dedicated to accelerating scientific breakthroughs and improving patient health and wellbeing, with a focus on basic and clinical research in the fields of endocrinology and diabetes. With over 18,000 members from 120 countries, the Endocrine Society is the largest endocrinological, scientific non-profit society in the world, dating back as far as 1916. Abstracts accepted for the annual meeting are published in the Journal of the Endocrine Society (JES) annual supplement.

Remedium will present data on the development of RMD1202, a first-in-class disease modifying gene therapy for the treatment of type 2 diabetes and obesity. RMD1202 is delivered with Remedium’s proprietary Prometheus™ platform, administered subcutaneously to enable continuous production of a GLP-1 receptor agonist (GLP-1 RA) in the subcutis, the same locale where treatments are currently delivered by a series of daily or weekly protein injections. Remedium’s latest findings suggest that the treatment is potentially superior to daily GLP-1 RA protein injections at promoting weight loss and enables enhanced insulin sensitivity and glucose response over the vehicle control.

“We are excited by the opportunity to present our work on RMD1202, a first-in-class disease modifying gene therapy treatment for type 2 diabetes and obesity, at the 2024 ENDO”, said Frank Luppino, President and CEO of Remedium. “A durable, gene therapy approach to type 2 diabetes and obesity, for the first time, offers the hope of a truly accessible and sustainable global treatment for these highly debilitating conditions.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 27, 2024 – Remedium Bio announced today that the company was invited to give a keynote podium presentation at the 15th Drug Discovery Strategic Summit (DDSS). This year’s DDSS is taking place May 8th and 9th at the Embassy Suites, Hilton, Boston. The event is focused on disruptive drug discovery, pharma and biotech partnerships, collaboration, and innovation in the fields of cell and gene therapies, recombinant proteins, and small molecule pharmaceuticals. Remedium will present data from its AI-powered high-throughput screening Prometheus™ platform, which enables drug discovery from target to in vivo efficacy in as little as 6 months.

“We are honored by the invitation to present a keynote talk at the 15th Strategic Drug Discovery Summit” said Frank Luppino, President and CEO of Remedium. “Our team will present Remedium’s innovative approach to drug discovery and the application of the Prometheus™ first-in-class dose adjustable gene therapy platform to the rapid advancement of biologics through preclinical efficacy”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 19, 2024 – Remedium Bio is excited to announce that the company has been invited to present at the 4th Annual Next Generation Gene Therapy Vectors Summit in Boston, MA. Remedium will highlight its Prometheus™ dose adjustable gene therapy platform technology and the lead candidate RMD1202, a disease modifying gene therapy for the treatment of type 2 diabetes and obesity. RMD1202 is the only single injection gene therapy treatment candidate for type 2 diabetes and obesity with the possibility of dose adjustment following initial administration. In addition to the significant advantages in cost over current alternatives, RMD1202 provides the possibility to eliminate pharmacokinetic spike related gastrointestinal side effects, which are associated with current multi-dose approaches. Remedium’s podium presentation titled “Prometheus™: The First Adjustable Dose Gene Therapy Platform Technology” will be presented on Jun 14 at 11:00 am ET.

“We are grateful for the invitation to present our dose adjustable gene therapy platform technology – Prometheus™ at the 4th Annual Next Generation Gene Therapy Vectors Summit in Boston”, said Frank Luppino, President and CEO of Remedium. “We aim to validate this revolutionary technology in a first-in-human study of RMD1202, a single injection treatment for type 2 diabetes and obesity”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 5, 2024 – Remedium announced today the publication of a manuscript titled “Single Injection AAV2-FGF18 Gene Therapy Reduces Cartilage Loss and Subchondral Bone Damage in a Mechanically Induced Model of Osteoarthritis” in the peer reviewed journal Current Gene Therapy.

Osteoarthritis (OA) is a chronic degenerative disease characterized by progressive loss of cartilage, leading to pain, loss of function, and disability. Affecting an estimated 500 million people around the globe, OA is the largest unmet clinical need in rheumatology, with no currently approved disease modifying treatments.

RMD1101 is a novel, investigational gene therapy and is the only single-injection treatment based on the regenerative mechanism of the FGF18 protein. The findings highlighted in the study demonstrate an unprecedented effect on disease progression, and a unique set of advantages of the gene therapy approach to treating Osteoarthritis.

Key highlights include:

- High treatment localization within the joint capsule and long-term durability following intra articular AAV2-FGF18 delivery.
- Significant protection of hyaline cartilage after a single injection of RMD1101 (AAV2-FGF18), superior to chondroprotection achieved by the repeat FGF18 protein treatment regimen.
- Improved safety profile compared to intra-articular protein injections, as a result of the single injection treatment paradigm, which prevents repeat joint capsule disruption.
- Protection of natural subchondral bone architecture from osteoarthritic remodeling and prevention of subchondral bone void formation.
- Improved gene expression, which results in the maintenance and homogeneity of the critical hyaline cartilage boundary layer lubricating protein PRG4 (lubricin).

“We are honored to have Current Gene Therapy publish our manuscript highlighting RMD1101’s unique safety and efficacy profile” said Frank Luppino, President and CEO of Remedium. “The study findings confirm the advantages of gene therapy over repeat protein injection regimens, providing hope that a single-injection, truly disease modifying treatment for osteoarthritis may be a future possibility for patients”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jan 16, 2023 – Remedium Bio announced today the acceptance of an abstract titled “AAV2-FGF18 gene therapy protects against cartilage loss and subchondral bone remodeling in a mechanically induced model of osteoarthritis” for the 2024 Orthopedic Research Society (ORS) Annual Meeting. This year’s ORS annual meeting will take place in Long Beach, California February 2nd through the 6th at the Long Beach Convention Center. This 70th anniversary event will bring together an estimated 2,500 orthopedic thought leaders from academia and industry, to review the most current clinical and preclinical research in the field of musculoskeletal disorders.

“We are honored by the selection to present our abstract at this year’s inaugural event and looking forward to highlighting our most recent findings on the safety and efficacy of RMD1101, the only single injection disease modifying osteoarthritis therapy based on the mechanisms of FGF18” said Frank Luppino, President and CEO of Remedium.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Nov 2, 2023 – Remedium Bio announced today the acceptance of an abstract titled “Treatment with rhFGF18 Appears Cerebroprotective in Model of Ischemic Stroke” at the 7th International Neurology and Brain Disorders Conference. This year INBD event is taking place virtually and in person in Dubai, UAE and Remedium will present its work as a virtual podium talk. This year’s conference theme is “Integrated Approach for Identifying Solutions in the Field of Neurology and Brain Disorders” and covers interventional pharmaceutical and biological treatments for ischemic and hemorrhagic stroke. Remedium will highlights its pipeline candidate RMD1501, which has shown potential for increased survival, improved motor cognitive function, and neuro- and cerebro-protection in a well-characterized model of transient cerebral ischemia.

“We are honored to have been selected to present at the 7th International Neurology and Brain Disorders Conference” said Frank Luppino, President and CEO of Remedium. “The invitation to present our novel investigational candidate for the treatment of ischemic stroke, as a virtual podium talk at this event, highlights the advances made by our team on the development of Remedium’s pipeline asset for the treatment of cerebral ischemia”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Sep 19, 2023 – Remedium Bio announced today the acceptance of an abstract describing the safety and efficacy of an investigational neuroprotective treatment for ischemic stroke RMD 1501. The abstract titled “Treatment with rhFGF18 appears cerebroprotective in model of ischemic stroke” was accepted for opening day podium presentation at the 8th Edition of International Conference on Neurology and Brain Disorders (INBC) taking place in Boston, October 19th through the 21st. This year’s INBC event is focusing on the theme of BRAIN “Bolstering & Renovating Advanced techniques In Neurology” with an emphasis on neuroprotective and neuroregenrative therapeutics for the treatment of brain disorders.

“We are honored to have been accepted to present our abstract as an opening day podium talk at the 2023 INBC in Boston” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for such a high-profile event highlights the advances made by the team on the development of Remedium’s pipeline asset for the treatment of cerebral ischemia”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Sep 5, 2023 - Remedium Bio announces the acceptance of an abstract titled “Development of a novel lipid nanoparticle-based adjustable gene therapy platform technology” for the 2023 American Society of Human Genetics (ASHG) annual conference. This year’s 75th anniversary ASHG will take place in Washington, DC on November 1st through 5th as a live, in-person event. The work presented will unveil Remedium’s dose adjustable gene therapy platform technology - Prometheus™. The revolutionary gene therapy system developed by Remedium, is a first-in-class, ultra-low cost, dose adjustable gene therapy platform intended for replacing subcutaneous protein injection regimens with a single treatment gene therapy. The system is designed with unique tropism and optimized to eliminate pharmacokinetic sawtoothing related side-effects and suboptimal efficacy profiles associated with many injectable protein therapies.

The American Society of Human Genetics is a professional, scientific, and medical society, which includes over 8,000 scientists from over 80 countries with the goal of translating new genetic knowledge to propel biomedical research. This year’s event is anticipating over 5,000 attendees and over 3,000 presented conference posters.

“We are honored to have been accepted to present our abstract as a podium talk at the 75th annual ASHG” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for such a selective meeting highlights the advances made by the team on the development of Remedium’s revolutionary, first-in-class, dose adjustable gene therapy platform technology”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jun 1, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “rhFGF18 and rhGDF11 for the Treatment of Ischemic Stroke” for the 2023 International Conference on Neurology and Neurological Disorders. This year’s conference is organized in collaboration with the Journal of Integrative Neuroscience and will take place in Rome, Italy June 16th and 17th as a live in-person or virtual online event. The work presented will highlight Remedium’s progress in the development of a novel treatment for ischemic stroke. This year’s Magnus Group event includes tracks on Neurological Disorders and Stroke, Brain Injury and Behavioral Neuroscience, as well as Clinical and Translational Neurology.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our innovative treatment for the management of ischemic stroke” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract at this prestigious meeting highlights the advances made by the team on the development of Remedium’s innovative pipeline of disease modifying therapies for age-related pathologies”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, May 1, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “FGF18 Gene Therapy Treatment for Osteoarthritis Promotes Regenerative Chondroanabolic and Anti-Catabolic Activity” for the 8th Annual Skeletal Research Symposium (ASRS). This year’s ASRS will take place on May 8th, in Boston, as a live in-person event at the Mass General Hospital (MGH) Main Campus. The work presented will highlight Remedium’s progress in the development of a novel potentially disease modifying treatment for Osteoarthritis, which is based on the chondrogenic mechanism of FGF18. The abstract will highlight the latest safety, efficacy, durability, and mechanistic findings from the preclinical studies comparing a single injection FGF18 gene therapy treatment to a series of protein injections and a placebo control.

“We are very excited for the opportunity to present our work at the 8th Annual Skeletal Research Symposium” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract for this prestigious, MGH-organized event, highlights the advances made by the team on the development of Remedium’s first-in-class potentially disease modifying gene therapy for Osteoarthritis”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 10, 2023 - Remedium Bio, a biotechnology company developing advanced therapies in the fields of rheumatology, endocrinology, and neurology, today announced the acceptance of an abstract entitled “Treatment with rhFGF18 Analog Results in Cerebroprotection and Recovery of Motor and Memory Function in a Rat Model of Acute Ischemic Stroke” for the 2023 American Academy of Neurology (AAN) annual meeting. This year’s AAN will take place in Boston, Massachusetts April 22nd through the 27th as a live in-person or virtual online event. The work presented will highlight Remedium’s progress in the development of a novel treatment for ischemic stroke. The American Academy of Neurology is a professional, scientific, and medical society established in 1948 with a current membership of over 38,000 scientists and clinical researchers representing the fields of neurology, neuroimmunology, and neural genetics.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our innovative treatment for the management of ischemic stroke at 2023 AAN” said Frank Luppino, President and CEO of Remedium, “The acceptance of our abstract at such a prestigious conference highlights the advances made by the team on the development of Remedium’s innovative pipeline of disease modifying therapies”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 5, 2023 - Remedium Bio is pleased to announce the appointment of Charles Sherwood, Ph.D., as a Corporate Advisor for the company. Dr. Sherwood brings a wealth of experience building companies that have created significant value developing products for Osteoarthritis and cartilage regeneration. Dr. Sherwood will advise on corporate strategy and the company’s lead candidate disease modifying gene therapy for Osteoarthritis.

Dr. Sherwood is the Founder of Sherwood Ventures, a firm focused on early-stage life science company investments. Dr. Sherwood was previously the CEO of Anika Therapeutics, a global, publicly traded regenerative medicine company engaged in the discovery, preclinical and clinical development, approval, and commercialization of restorative and regenerative treatments, with a focus in Rheumatology. Dr. Sherwood brought to the market leading OA palliative therapies including Monovisc®, Orthovisc®, and Cingal®. In addition, he led the development and industrialization of Hyalofast®, a single-step cartilage regenerative solution for focal cartilage defects. Under his leadership, the OA-focused company with a $6M market cap grew to a highly-profitable multinational corporation with a distribution network in over 85 countries.

"We are extremely excited to onboard Dr. Sherwood in this important advisory role at this transformational inflection point for Remedium” said Frank Luppino, President and CEO of Remedium Bio. “We look forward to levering Dr. Sherwood’s deep experience and business expertise in rheumatology, product development, and strategic partnering as we continue to advance our lead disease-modifying Osteoarthritis product and novel platform technology”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Mar 13, 2023 - Remedium Bio, a gene therapy company developing novel treatments for significant unmet needs, today announced the publication of pre-clinical data demonstrating the safety and chondrogenic activity of RMD1101, its innovative gene therapy for Osteoarthritis. These data are the first to be published from Remedium’s ongoing research collaboration with Tufts University studying the approach. The paper, entitled “Adeno-Associated Virus-Delivered Fibroblast Growth Factor 18 Gene Therapy Promotes Cartilage Anabolism” will be published in Volume 14, Issue 1 of the journal Cartilage, and is available OnlineFirst.

Key Points

- AAV2-FGF18 appears to have a wide therapeutic safety window and is able to induce chondrogenesis at very low, locally administered doses
- The FGF18 gene therapy appears to induce chondrogenesis by increasing hyaline cartilage associated gene expression and promoting chondrocyte proliferation
- RMD1101 appears safe and effective at promoting cartilage anabolism in vivo, following a single intra articular injection

“Having these results published in Cartilage provides important external validation of their significance” said Frank Luppino, President and CEO of Remedium. “Our findings confirm the chondrogenic mechanism after a single injection of RMD1101 and provide preliminary confirmation for the potential of the gene therapy approach to treating Osteoarthritis.” RMD1101 is the only disease modifying gene therapy treatment for Osteoarthritis based on the clinically validated chondrogenic mechanism of FGF18. It is being studied as a single injection treatment for OA in both the human and companion animal markets. “Our results show the promise of treating Osteoarthritis by harnessing the endogenous regenerative power of articular cartilage with a single intra-articular injection FGF18 gene therapy,” said Dr. Li Zeng, PhD, Associate Professor of Immunology at Tufts University School of Medicine. Dr. Zeng is a co-author of the publication and an expert in Osteoarthritis and the molecular and cellular mechanisms of the disease.

Cartilage is a peer-reviewed, open access journal which publishes articles with a focus on recent discoveries related to the musculoskeletal system and cartilage repair, development, and regeneration. The Sage Publishing group, MEDLINE indexed journal publishes full length original manuscripts covering preclinical and clinical research, and is considered among the top journals in the field of cartilage regeneration.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 6, 2023 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract titled “AAV2-FGF18 Repairs Cartilage in Disease Model of Osteoarthritis” for the 2023 Tissue Engineering Strategies for Human Health and Longevity conference. This year’s event will take place at the Marriott Copley Place in Boston as a live, in-person meeting. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, a single-injection treatment potentially capable of reversing cartilage loss in OA. The Tissue Engineering and Regenerative Medicine International Society (TERMIS) is a professional, scientific, and medical society with a mission of advancing tissue engineering and regenerative medicine to generate knowledge with a view to improving patient outcomes.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 Boston TERMIS” said Frank Luppino, President and CEO of Remedium, “We are excited to share the recently generated preclinical safety and efficacy data highlighting the regenerative potential of RMD1101 in the treatment of a range of cartilage pathologies”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jan 10, 2023 - Remedium Bio, announces the acceptance of an abstract titled “Novel AAV2-FGF18 Gene Therapy Promotes Cartilage Anabolism” for Podium Presentation at the 50th Annual Veterinary Orthopedic Society (VOS) Conference. This year’s VOS will take place Mar 11-18th at Big Sky, Montana bringing together academics, researchers, and veterinarians to discuss the latest discoveries in veterinary orthopedics, traumatology, and regenerative medicine. The research presented will provide an overview of Remedium’s progress in the development of a novel, potentially disease modifying gene therapy for the treatment of Osteoarthritis, and its advantages specifically for veterinary medicine.

VOS is the leading veterinary medicine society focused on orthopedics and osteoarthritis, having provided a podium for the presentation of veterinary orthopedic discoveries for over 50 years. The VOS abstracts are published in the Veterinary and Comparative Orthopaedics and Traumatology (VCOT) Journal and made available online at the Veterinary Orthopedic Society website. “We are very excited to have been accepted to present our abstract reviewing veterinary medicine potential of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 VOS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment and its significant translational potential for the treatment of companion animals”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Dec 6, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “Novel AAV2-FGF18 Chondrogenic Gene Therapy” for the 2023 Osteoarthritis Research Society International (OARSI) conference. The 2023 OARSI World Congress on Osteoarthritis will take place March 17th through 20th in Denver Colorado. The studies presented will provide an overview of Remedium’s progress in the development of a novel gene therapy for the treatment of Osteoarthritis, highlighting the potential of the company’s first-in-class chondrogenic gene therapy treatment.

OARSI is a leading international medical society for the advancement of understanding, early detection, treatment, and prevention of Osteoarthritis – a highly debilitating disease affecting more than 600 million people worldwide. For over 30 years, OARSI brings together scientists and engineers at the annual World Congress on Osteoarthritis. All abstracts presented at the Congress are published in the supplement to OARSI’s journal, Osteoarthritis and Cartilage. “We are very excited to have been accepted to present our abstract reviewing the safety and efficacy of our first-in-class chondrogenic gene therapy treatment for Osteoarthritis at the 2023 OARSI” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation is an important milestone highlighting the progress we have made to date developing this novel treatment”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Nov 15, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying gene therapy for the treatment of Osteoarthritis (OA) announced today the acceptance of an abstract titled “AAV2-hFGF18 Increases Cartilage Thickness and Promotes Hyaline Cartilage Anabolism” for the Orthopedic Research Society (ORS) Conference. The 2023 ORS meeting will take place February 10th through 14th in Dallas Texas. Remedium’s abstract was selected to be presented at the Podium Spotlight Session on February 13th, highlighting therapeutic delivery to joints. The work presented will review Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss, based on the clinically proven mechanism of FGF18.

Dating back to 1954, the Orthopedic Research Society is a global organization focused on musculoskeletal research. Today, the ORS consists of over 4000 members in nearly 50 countries, representing researchers, clinicians, and veterinarians. “We are very excited to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2023 ORS” said Frank Luppino, President and CEO of Remedium; “The selection of our abstract for a podium presentation spotlight session is an important milestone highlighting the progress we have made to date”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Nov 8, 2022 – Remedium Bio, Inc., a biotechnology company developing novel gene therapies for large unmet needs, today announced the appointment of Richard Hague to its Board of Directors. Mr. Hague is an accomplished biotechnology executive with extensive multi-discipline experience in rheumatology and with regenerative therapies. "Richard is a highly valued addition to the Remedium team, and his background and expertise across three decades in the industry, with many successes in osteoarthritis and regenerative medicine, will help guide Remedium’s strategy and portfolio development as we embark on the next phase of our growth” said Frank Luppino, CEO of Remedium. "We welcome Richard to our Board and look forward to his contributions.”

“Since inception, Remedium has rapidly built a strong portfolio of novel gene therapies,” said Mr. Hague. “I am excited to join the Board of Directors at this pivotal stage for the company, and eager to help bring the unique advantages of gene therapy to the treatment of osteoarthritis.”

Mr. Hague is currently the President and Chief Executive Officer of PolarityTE, a regenerative medicine company developing its lead cell therapy product for the treatment of complex wounds. Before joining PolarityTE, Mr. Hague was the Chief Commercial Officer at Anika Therapeutics, where he led all global commercial activities and had oversight of the R&D and Clinical Research functions. He spent a significant portion of his career at Genzyme and later Sanofi (following Sanofi’s acquisition of Genzyme), where he held positions of increasing responsibility, culminating in his role as VP/General Manager of Sanofi’s Cell Therapy and Regenerative Medicine Business Unit. While at Genzyme, Richard played an integral role in the launch and adoption of the first autologous cell therapy products used in orthopedics and burns. Subsequently, he has led the development and launch of innovative products in multiple markets via the CBER and CDRH regulatory pathways.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Aug 8, 2022 - Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an abstract entitled “Characterization of a Novel FGF18 Gene Therapy for the Treatment of Osteoarthritis” for the 2022 Annual American Society of Bone and Mineral Research (ASBMR) meeting. This year’s ASBMR will take place in Austin Texas on September 9th through 12th as an in-person live event. The work presented will highlight Remedium’s progress in the development of a novel gene therapy for the treatment of OA, which is the only single-injection treatment potentially capable of reversing cartilage loss in OA, based on the clinically proven mechanism of FGF18. The American Society for Bone and Mineral Research is a professional, scientific, and medical society established in 1977 with a current membership of over 4,000 worldwide scientists and clinical researchers representing the fields of orthopedics, rheumatology, and pharmacology.

“We are honored to have been accepted to present our abstract reviewing the progress made to date in the development of our FGF18 gene therapy treatment for Osteoarthritis at the 2022 ASBMR” said Frank Luppino, President and CEO of Remedium, “We have been additionally invited to present a plenary poster on the first day of the event and are looking forward to sharing our findings at this prestigious forum”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jul 12, 2022 - Remedium Bio, a biotechnology company developing innovative gene therapies, today announced the acceptance of an abstract entitled “Novel High Efficiency Gene Delivery System for Human Primary Preadipocytes and Adipocytes” for the presentation of a poster at the 2nd Annual Next Generation Gene Therapy Vectors Summit in Boston. The work presented will highlight Remedium’s progress in the development of a novel gene delivery technology for use in its Type 2 Diabetes program. This technology is being evaluated in a collaboration at the University of Massachusetts Boston, with Professor Kai Zou’s laboratory, and is intended to support a number of therapeutic indications in Remedium’s pipeline.

The 2nd Annual Next Generation Gene Therapy Vectors Summit is taking place in Boston on July 18th to 20th, bringing together C-suite leaders, R&D experts, and Business Development professionals from Boston’s leading pharma and biotech companies. “We are excited to present data highlighting the progress on our gene delivery technology”, said Frank Luppino, President and CEO of Remedium; “The Next Generation Gene Therapy Vectors Summit is an important milestone for Remedium, as this technology potentially enables treatments in a number of therapeutic indications.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, May 25, 2022 - Remedium Bio announced today the acceptance of its abstract entitled “Novel FGF-18 Gene Therapy for the Treatment of Osteoarthritis” for presentation of a poster at the 4th Annual Longevity Therapeutics Summit. The poster will present results from preclinical studies of Remedium’s gene therapy for the treatment of Osteoarthritis (OA). FGF18 has been shown to result in structural improvement in OA patients in a Phase 2, placebo controlled, randomized clinical trial. Remedium’s novel gene therapy is a first in class, single-injection, potentially disease-modifying OA treatment, based on the proven chondroregenerative mechanism of FGF-18. Osteoarthritis is the most common form of arthritis and the largest unmet need in rheumatology, affecting an estimated 500 million people worldwide. Currently, there are no approved disease-modifying OA treatments capable of slowing or reversing disease progression.

The Longevity Therapeutics Summit is taking place in San Francisco on Jun 28th to 30th, bringing together over 100 leading biotech and pharma drug developers, academics, and investors. “We are excited to present data demonstrating proof of concept and the potential unique benefits of our novel gene therapy”, said Frank Luppino, President and CEO of Remedium; “The Longevity Therapeutics Summit is an important milestone for Remedium, and is the first in a series of presentations highlighting the encouraging data being generated on our potentially disease modifying treatment for Osteoarthritis.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Apr 7, 2022 - Remedium is excited to announce the appointment of Dr. Jeff L. Ellsworth as a scientific advisor for the company’s Rheumatology portfolio. Dr. Ellsworth led the R&D team that originally discovered FGF18’s ability to regenerate cartilage and alleviate infarct-induced injury in an animal model of stroke. He has led several R&D functions at companies including CV Therapeutics, ZymoGenetics, Moderna, and Homology Medicines, and is a renowned authority on Osteoarthritis therapeutics in general and the FGF18 protein specifically. Jeff is also a sought after consultant with a successful track record of providing strategic guidance to emerging biotechnology companies. Jeff holds a PhD in Pharmacology and Cell Biophysics from the University of Cincinnati College of Medicine and a Bachelor of Science in Chemistry from the Indiana University Bloomington. Upon completion of his dissertation defense, Jeff spent a number of years as a post-doctoral fellow at Stanford University School of Medicine researching lipoprotein receptors and lipid metabolism.

"Jeff is a perfect addition to Remedium’s team of advisors given his pivotal role in the discovery of FGF18’s regenerative potential, and strong track record developing a number of highly impactful regenerative therapies" said Frank Luppino, CEO of Remedium Bio. "Jeff will add significant value to Remedium’s R&D activities, including our lead candidate and pipeline products, and we are extremely excited to partner with him.”

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Feb 24, 2022 - Remedium is excited to announce the appointment of Dr. Li Zeng, Associate Professor of Immunology as a scientific advisor for the company’s Rheumatology portfolio. Dr. Zeng currently holds the position of Associate Professor of Immunology at the Graduate School of Biomedical Sciences at Tufts University. She holds a PhD and MA in Cell & Molecular Biophysics from Columbia University with Postdoctoral training at the Harvard Medical School, an MS in Biochemistry from Tsinghua University, and a BA in Plant Physiology & Biochemistry from the Beijing Agricultural University. Currently, Dr. Zeng leads an integrated research laboratory at the Tufts University, Graduate School of Biomedical Sciences focusing on Osteoarthritis research. Her laboratory has generated high-impact publications in journals including Nature Scientific Reports, Nature Laboratory Investigations, Development, Journal of Clinical Investigations, and Osteoarthritis and Cartilage.

"We are extremely excited to partner with Dr. Li Zeng in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Dr. Zeng is a world-renowned authority who brings a wealth of scientific and mechanistic knowledge to the company enabling further validation of our potentially disease modifying gene therapy for Osteoarthritis”.

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jul 12, 2021 - Remedium is excited to announce that Dr. Timothy McAlindon, MD, MPH is serving as a scientific and medical advisor for the company’s Rheumatology portfolio. Dr. McAlindon is the Chief of the Division of Rheumatology at the Tufts Medical Center and Professor of Medicine at Tufts University School of Medicine. He is a recognized Key Opinion Leader in Rheumatology, having led the American College of Rheumatology (ACR) Rheumatoid Arthritis (RA) Clinical Treatment Guideline Literature Review Team and chaired the Osteoarthritis Research Society International (OARSI) Treatment Guideline Development Committee. Dr. McAlindon received his Doctorate in of Medicine and Bachelor of Medicine from the University of Southhampton Medical School, his MPH from Boston University School of Public Health, and completed medical training at the Bristol Royal Infirmary, and St. Thomas' Hospital in London, and the Royal United Hospital in the UK. Tim is board certified in Internal Medicine and Rheumatology and is a recipient of a number of prestigious honors and awards including Top Doctor from Boston Magazine and the U.S. News & World Report, 2018 Distinguished Clinical Research Achievement Award from the Clinical Research Forum, as well as the ACR REF Amgen Wyeth Rheumatology Fellowship Training Award. Dr. McAlindon is an author of numerous scientific publications in a broad range of high-impact factor journals including the Journal of the American Medical Association (JAMA) and Annals of Internal Medicine with a research focus in Rheumatoid and Osteoarthritis. "We are extremely excited to partner with Dr. Tim McAlindon in this important advisory role, supporting our lead candidate Rheumatology gene therapy" said Frank Luppino, CEO of Remedium Bio. "Tim is a world-renowned authority who brings a wealth of scientific, regulatory, and clinical experience that enables further validation of our exciting pipeline".

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.

BOSTON, Jun 30, 2021 - Remedium Bio, Inc. is extremely excited to announce that Dr. Anastassios Pittas will serve as a Scientific and Medical Advisor on the company’s Endocrinology portfolio. Dr. Pittas is the Chief of the Division of Endocrinology, Diabetes, and Metabolism and Professor of Medicine at Tufts University. He is a recipient of a number of prestigious honors and awards including multiple consecutive Top Doctor awards from Boston Magazine, Biomedical Research Exemplar Award which honors individuals doing high-quality, high-impact, federally-funded research who also maintain an impressive reputation for professionalism and integrity in their work as well as the Donna Seto-Young Award, which recognizes meritorious achievement in the advancement of science, education, practice of medicine or improvement of human health and well-being. Dr. Pittas holds a Bachelor of Science in Biology from MIT, a Master of Science in Clinical Research from the Sackler School of Biomedical Sciences at Tufts University, an MD from the Weill Medical College of Cornell University, completed his Internal Medicine Residences at the New York Presbyterian Hospital, and a Fellowship in Endocrinology, Diabetes, and Metabolism at the Tufts Medical Center. "Partnering with Dr. Pittas brings significant subject matter expertise in Endocrinology and helps Remedium validate its multiple Diabetes pipeline candidates from a clinical perspective" said Frank Luppino, CEO of Remedium Bio. "We are extremely excited to be working with Dr. Pittas and are looking forward to evaluating our novel and proprietary approaches to treating Type 1 and Type 2 diabetes with gene therapy".

Contact Remedium: info@remedium-bio.com
Source: Remedium Bio, Inc.